IL254254B - chimeric antigen receptor - Google Patents
chimeric antigen receptorInfo
- Publication number
- IL254254B IL254254B IL254254A IL25425417A IL254254B IL 254254 B IL254254 B IL 254254B IL 254254 A IL254254 A IL 254254A IL 25425417 A IL25425417 A IL 25425417A IL 254254 B IL254254 B IL 254254B
- Authority
- IL
- Israel
- Prior art keywords
- antigen receptor
- chimeric antigen
- chimeric
- receptor
- antigen
- Prior art date
Links
- 108010019670 Chimeric Antigen Receptors Proteins 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/14—Blood; Artificial blood
- A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/10—Cellular immunotherapy characterised by the cell type used
- A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/30—Cellular immunotherapy characterised by the recombinant expression of specific molecules in the cells of the immune system
- A61K40/31—Chimeric antigen receptors [CAR]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
- A61K40/41—Vertebrate antigens
- A61K40/42—Cancer antigens
- A61K40/4202—Receptors, cell surface antigens or cell surface determinants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
- A61K40/41—Vertebrate antigens
- A61K40/42—Cancer antigens
- A61K40/4202—Receptors, cell surface antigens or cell surface determinants
- A61K40/421—Immunoglobulin superfamily
- A61K40/4211—CD19 or B4
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
- A61K40/41—Vertebrate antigens
- A61K40/42—Cancer antigens
- A61K40/4244—Enzymes
- A61K40/4251—Kinases, e.g. Raf or Src
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
- C12N5/0636—T lymphocytes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
- C12N5/0646—Natural killers cells [NK], NKT cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
- A61K2239/10—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterized by the structure of the chimeric antigen receptor [CAR]
- A61K2239/23—On/off switch
- A61K2239/24—Dimerizable CARs; CARs with adapter
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/622—Single chain antibody (scFv)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
- C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2510/00—Genetically modified cells
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Immunology (AREA)
- Biomedical Technology (AREA)
- Genetics & Genomics (AREA)
- Zoology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Biotechnology (AREA)
- Wood Science & Technology (AREA)
- Medicinal Chemistry (AREA)
- Cell Biology (AREA)
- Biochemistry (AREA)
- Hematology (AREA)
- Pharmacology & Pharmacy (AREA)
- Microbiology (AREA)
- General Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Toxicology (AREA)
- Gastroenterology & Hepatology (AREA)
- Oncology (AREA)
- Developmental Biology & Embryology (AREA)
- Virology (AREA)
- Peptides Or Proteins (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB1504840.8A GB201504840D0 (en) | 2015-03-23 | 2015-03-23 | Chimeric antigen receptor |
| PCT/GB2016/050795 WO2016151315A1 (en) | 2015-03-23 | 2016-03-22 | Chimeric antigen receptor |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| IL254254A0 IL254254A0 (en) | 2017-10-31 |
| IL254254B true IL254254B (en) | 2021-04-29 |
Family
ID=53052211
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL254254A IL254254B (en) | 2015-03-23 | 2017-08-31 | chimeric antigen receptor |
Country Status (21)
| Country | Link |
|---|---|
| US (1) | US11058722B2 (enExample) |
| EP (1) | EP3274366B8 (enExample) |
| JP (3) | JP6675417B2 (enExample) |
| KR (1) | KR102174280B1 (enExample) |
| CN (1) | CN107406518B (enExample) |
| AU (1) | AU2016238583B2 (enExample) |
| BR (1) | BR112017018252A2 (enExample) |
| CA (1) | CA2978852C (enExample) |
| CL (1) | CL2017002413A1 (enExample) |
| DK (1) | DK3274366T3 (enExample) |
| ES (1) | ES2773527T3 (enExample) |
| GB (1) | GB201504840D0 (enExample) |
| HU (1) | HUE047929T2 (enExample) |
| IL (1) | IL254254B (enExample) |
| MX (1) | MX371384B (enExample) |
| PL (1) | PL3274366T3 (enExample) |
| PT (1) | PT3274366T (enExample) |
| RU (1) | RU2752880C2 (enExample) |
| SG (1) | SG11201706940QA (enExample) |
| WO (1) | WO2016151315A1 (enExample) |
| ZA (1) | ZA201705682B (enExample) |
Families Citing this family (51)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SG11201505858VA (en) | 2013-01-28 | 2015-09-29 | St Jude Childrens Res Hospital | A chimeric receptor with nkg2d specificity for use in cell therapy against cancer and infectious disease |
| US11385233B2 (en) | 2015-03-05 | 2022-07-12 | Autolus Limited | Methods of depleting malignant T-cells |
| US11982672B2 (en) | 2014-03-05 | 2024-05-14 | Autolus Limited | Methods |
| GB201403972D0 (en) | 2014-03-06 | 2014-04-23 | Ucl Business Plc | Chimeric antigen receptor |
| GB201405845D0 (en) | 2014-04-01 | 2014-05-14 | Ucl Business Plc | Signalling system |
| EP3805371A1 (en) | 2014-05-15 | 2021-04-14 | National University of Singapore | Modified natural killer cells and uses thereof |
| GB201415347D0 (en) | 2014-08-29 | 2014-10-15 | Ucl Business Plc | Signalling system |
| GB201501936D0 (en) * | 2015-02-05 | 2015-03-25 | Ucl Business Plc | Signalling system |
| DK3298033T4 (da) | 2015-05-18 | 2023-10-02 | Tcr2 Therapeutics Inc | Sammensætninger og medicinske anvendelser til tcr-reprogrammering under anvendelse af fusionsproteiner |
| WO2017180587A2 (en) | 2016-04-11 | 2017-10-19 | Obsidian Therapeutics, Inc. | Regulated biocircuit systems |
| GB201610512D0 (en) | 2016-06-16 | 2016-08-03 | Autolus Ltd | Chimeric antigen receptor |
| JP7109789B2 (ja) | 2016-08-02 | 2022-08-01 | ティーシーアール２ セラピューティクス インク． | 融合タンパク質を使用したｔｃｒの再プログラム化のための組成物及び方法 |
| CA3036745A1 (en) | 2016-10-07 | 2018-04-12 | TCR2 Therapeutics Inc. | Compositions and methods for t-cell receptors reprogramming using fusion proteins |
| CA3044593A1 (en) | 2016-11-22 | 2018-05-31 | TCR2 Therapeutics Inc. | Compositions and methods for tcr reprogramming using fusion proteins |
| MX2019011570A (es) | 2017-03-27 | 2019-11-18 | Nat Univ Singapore | Lineas celulares estimuladoras para expansion y activacion ex vivo de celulas asesinas naturales. |
| IL269553B2 (en) | 2017-03-27 | 2025-10-01 | Nat Univ Singapore | Truncated NKG2D chimeric receptors and their uses in immunotherapy with natural killer cells |
| JP2020511992A (ja) * | 2017-03-29 | 2020-04-23 | サニーブルック リサーチ インスティテュート | 遺伝子組換えｔ細胞調節分子およびその使用方法 |
| US11166985B2 (en) | 2017-05-12 | 2021-11-09 | Crispr Therapeutics Ag | Materials and methods for engineering cells and uses thereof in immuno-oncology |
| EP3621981A2 (en) | 2017-05-12 | 2020-03-18 | CRISPR Therapeutics AG | Materials and methods for engineering cells and uses thereof in immuno-oncology |
| JP2020530993A (ja) * | 2017-08-02 | 2020-11-05 | オートラス リミテッド | キメラ抗原受容体または改変ｔｃｒを発現し、選択的に発現されるヌクレオチド配列を含む細胞 |
| JP2021500930A (ja) * | 2017-11-01 | 2021-01-14 | エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ | Ｃｏｍｐボディ−多価標的結合物質 |
| GB201801831D0 (en) * | 2018-02-05 | 2018-03-21 | Autolus Ltd | Chimeric receptor |
| US12258381B2 (en) | 2018-02-09 | 2025-03-25 | National University Of Singapore | Activating chimeric receptors and uses thereof in natural killer cell immunotherapy |
| CN112055717B (zh) | 2018-04-02 | 2024-04-26 | 新加坡国立大学 | 用在免疫细胞中表达的膜结合抗细胞因子非信号传导粘合剂中和人细胞因子 |
| CN112105420A (zh) | 2018-05-11 | 2020-12-18 | 克里斯珀医疗股份公司 | 用于治疗癌症的方法和组合物 |
| CN112119096B (zh) | 2018-05-15 | 2024-04-30 | 奥托路斯有限公司 | 嵌合抗原受体 |
| GB201807870D0 (en) | 2018-05-15 | 2018-06-27 | Autolus Ltd | A CD79-specific chimeric antigen receptor |
| CN112930186A (zh) * | 2018-08-16 | 2021-06-08 | 纪念斯隆-凯特琳癌症中心 | 基于亮氨酸拉链的组合物和使用方法 |
| EP3844186A4 (en) | 2018-08-29 | 2022-08-17 | National University of Singapore | METHOD OF SPECIFIC STIMULATION OF SURVIVAL AND EXPANSION OF GENETICALLY MODIFIED IMMUNE CELLS |
| CN109265550B (zh) * | 2018-09-25 | 2020-09-15 | 华东师范大学 | Bcma抗体、嵌合抗原受体和药物 |
| MX2021003636A (es) | 2018-09-27 | 2021-07-21 | Autolus Ltd | Receptor antigenico quimerico. |
| KR20210072797A (ko) * | 2018-10-05 | 2021-06-17 | 세인트 안나 킨더크렙스포르슝 | 키메라 항원 수용체(car) 그룹 |
| CA3109747A1 (en) * | 2018-10-05 | 2020-04-09 | St. Anna Kinderkrebsforschung | A group of chimeric antigen receptors (cars) |
| GB201817822D0 (en) | 2018-10-31 | 2018-12-19 | Autolus Ltd | Binding domain |
| WO2020172643A2 (en) * | 2019-02-21 | 2020-08-27 | Luk John M | Artificial immunosurveillance chimeric antigen receptor (ai-car) and cells expressing the same |
| KR20210137085A (ko) | 2019-03-05 | 2021-11-17 | 엔카르타, 인크. | Cd19 유도된 키메라 항원 수용체 및 면역 요법에서 이의 용도 |
| KR20210143246A (ko) | 2019-03-21 | 2021-11-26 | 리제너론 파아마슈티컬스, 인크. | 알레르기 치료용 il-4/il-13 경로 억제제 및 형질 세포 절제의 병용 |
| WO2020222176A1 (en) | 2019-04-30 | 2020-11-05 | Crispr Therapeutics Ag | Allogeneic cell therapy of b cell malignancies using genetically engineered t cells targeting cd19 |
| GB201919017D0 (en) | 2019-12-20 | 2020-02-05 | Autolus Ltd | Cell |
| CN111234033B (zh) * | 2020-01-21 | 2021-05-11 | 南京北恒生物科技有限公司 | 多链嵌合抗原受体及其用途 |
| GB202004263D0 (en) | 2020-03-24 | 2020-05-06 | Autolus Ltd | Antibody conjugate |
| GB202005216D0 (en) | 2020-04-08 | 2020-05-20 | Autolus Ltd | Cell |
| GB202006820D0 (en) | 2020-05-07 | 2020-06-24 | Autolus Ltd | Cell |
| GB202017649D0 (en) | 2020-11-09 | 2020-12-23 | Autolus Ltd | Polypeptide |
| WO2022182891A1 (en) | 2021-02-25 | 2022-09-01 | Lyell Immunopharma, Inc. | Ror1 targeting chimeric antigen receptor |
| US20250288672A1 (en) * | 2021-03-24 | 2025-09-18 | Raymond Liu | Humanized synthetic notch receptors with augmented transactivation domains and uses thereof |
| GB202115329D0 (en) * | 2021-10-25 | 2021-12-08 | Autolus Ltd | Chimeric cytokine receptor |
| WO2024019961A1 (en) * | 2022-07-18 | 2024-01-25 | Cargo Therapeutics, Inc. | Cd2 recruiting chimeric antigen receptors and fusion proteins |
| US20250242056A1 (en) | 2024-01-26 | 2025-07-31 | Regeneron Pharmaceuticals, Inc. | Methods and compositions for using plasma cell depleting agents and/or b cell depleting agents to suppress host anti-aav antibody response and enable aav transduction and re-dosing |
| US20250242018A1 (en) | 2024-01-26 | 2025-07-31 | Regeneron Pharmaceuticals, Inc. | Combination immunosuppression for inhibiting an immune response and enabling immunogen administration and re-administration |
| WO2025184567A1 (en) | 2024-03-01 | 2025-09-04 | Regeneron Pharmaceuticals, Inc. | Methods and compositions for re-dosing aav using anti-cd40 antagonistic antibody to suppress host anti-aav antibody response |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7081443B2 (en) | 2002-05-21 | 2006-07-25 | Korea Advanced Institutes Of Science And Technology (Kaist) | Chimeric comp-ang1 molecule |
| WO2010102518A1 (zh) | 2009-03-13 | 2010-09-16 | 北京表源生物技术有限公司 | 一种融合蛋白多聚体 |
| KR101156085B1 (ko) * | 2010-01-29 | 2012-06-20 | 국립암센터 | ４－１ｂｂ리간드（４－１ｂｂｌ）오중합체 및 이의 용도 |
| US10745467B2 (en) * | 2010-03-26 | 2020-08-18 | The Trustees Of Dartmouth College | VISTA-Ig for treatment of autoimmune, allergic and inflammatory disorders |
| JP6053688B2 (ja) * | 2011-10-07 | 2016-12-27 | 国立大学法人三重大学 | キメラ抗原受容体 |
| CN111676196A (zh) * | 2012-05-25 | 2020-09-18 | 塞勒克提斯公司 | 工程化异体和免疫抑制耐受性t细胞的方法 |
| DK2893004T3 (en) | 2012-09-04 | 2019-02-04 | Cellectis | MULTI-CHAIN CHEMICAL ANTIGEN RECEPTOR AND APPLICATIONS THEREOF |
| KR102332790B1 (ko) * | 2013-02-15 | 2021-12-01 | 더 리젠츠 오브 더 유니버시티 오브 캘리포니아 | 키메라 항원 수용체 및 이의 이용 방법 |
| CN103145849B (zh) * | 2013-02-18 | 2014-06-11 | 冯振卿 | 嵌合抗原受体及其用途 |
| PT3083671T (pt) * | 2013-12-20 | 2020-12-24 | Hutchinson Fred Cancer Res | Moléculas efetoras quiméricas etiquetadas e recetores destas |
| CN107074957B (zh) | 2014-01-13 | 2021-05-07 | 希望之城公司 | 在Fc间隔物区中具有突变的嵌合抗原受体(CAR)及其使用方法 |
| GB201415347D0 (en) | 2014-08-29 | 2014-10-15 | Ucl Business Plc | Signalling system |
| GB201610512D0 (en) | 2016-06-16 | 2016-08-03 | Autolus Ltd | Chimeric antigen receptor |
-
2015
- 2015-03-23 GB GBGB1504840.8A patent/GB201504840D0/en not_active Ceased
-
2016
- 2016-03-22 PT PT167124247T patent/PT3274366T/pt unknown
- 2016-03-22 JP JP2017549766A patent/JP6675417B2/ja not_active Expired - Fee Related
- 2016-03-22 RU RU2017132978A patent/RU2752880C2/ru active
- 2016-03-22 ES ES16712424T patent/ES2773527T3/es active Active
- 2016-03-22 PL PL16712424T patent/PL3274366T3/pl unknown
- 2016-03-22 BR BR112017018252-1A patent/BR112017018252A2/pt active Search and Examination
- 2016-03-22 EP EP16712424.7A patent/EP3274366B8/en active Active
- 2016-03-22 KR KR1020177030391A patent/KR102174280B1/ko active Active
- 2016-03-22 CA CA2978852A patent/CA2978852C/en active Active
- 2016-03-22 CN CN201680017370.3A patent/CN107406518B/zh active Active
- 2016-03-22 DK DK16712424.7T patent/DK3274366T3/da active
- 2016-03-22 MX MX2017010552A patent/MX371384B/es active IP Right Grant
- 2016-03-22 SG SG11201706940QA patent/SG11201706940QA/en unknown
- 2016-03-22 AU AU2016238583A patent/AU2016238583B2/en not_active Ceased
- 2016-03-22 US US15/560,558 patent/US11058722B2/en active Active
- 2016-03-22 WO PCT/GB2016/050795 patent/WO2016151315A1/en not_active Ceased
- 2016-03-22 HU HUE16712424A patent/HUE047929T2/hu unknown
-
2017
- 2017-08-21 ZA ZA2017/05682A patent/ZA201705682B/en unknown
- 2017-08-31 IL IL254254A patent/IL254254B/en active IP Right Grant
- 2017-09-25 CL CL2017002413A patent/CL2017002413A1/es unknown
-
2020
- 2020-01-09 JP JP2020001971A patent/JP2020048588A/ja not_active Withdrawn
-
2022
- 2022-12-16 JP JP2022201192A patent/JP2023021396A/ja not_active Withdrawn
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL254254B (en) | chimeric antigen receptor | |
| GB201503742D0 (en) | Chimeric antigen receptor | |
| SG11201606790XA (en) | Chimeric antigen receptor | |
| IL250536A0 (en) | Chimeric antigen receptors | |
| IL251030A0 (en) | Chimeric antigen receptors | |
| IL258527A (en) | Chimeric Antigen Receptors Against Sorting Group 30 | |
| PT3294764T (pt) | Composições de recetores de antigénios quiméricos | |
| IL252783A0 (en) | bcma chimeric antigen receptors | |
| GB201617290D0 (en) | Novel chimeric antigen receptors | |
| GB201607968D0 (en) | Chimeric antigen receptor | |
| ZA201700730B (en) | Bcma chimeric antigen receptors | |
| GB201610512D0 (en) | Chimeric antigen receptor | |
| EP3256496A4 (en) | Chimeric antigen receptors | |
| ZA201906321B (en) | Chimeric antigen receptor | |
| GB201709508D0 (en) | Chimeric antigen receptor | |
| GB201519900D0 (en) | Chimeric antigen receptor | |
| GB201721421D0 (en) | Chimeric antigen receptor | |
| GB201810451D0 (en) | Anti-placenta-chondroitin-sulfate chimeric antigen receptor and application thereof | |
| GB201612844D0 (en) | Chimeric antigen receptor | |
| GB201612533D0 (en) | Chimeric antigen receptor | |
| GB201604387D0 (en) | Chimeric antigen receptor | |
| GB201409761D0 (en) | Chimeric antigen receptor | |
| GB201403481D0 (en) | Chimeric antigen receptor |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FF | Patent granted | ||
| KB | Patent renewed |